Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT10109L vs BOTOX for Glabella Lines
NCT03894748Phase 3Completed
- Sponsor
- Medytox Inc.
- Start
- Dec 2011
- Primary completion
- Aug 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab + botulinumtoxinA in glabellar lines, sponsored by Medytox Inc.. Started Dec 2011; status: completed.
02
Drugs
nivolumab + botulinumtoxinA
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT03894748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03894748.